ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
South San Francisco-based Titan Pharmaceuticals is cutting 40% of its workforce to save cash. The remaining staff of about 25, which is likely to be further cut, will conduct minimal development efforts to keep the company's Phase III probuphine opioid addiction treatment afloat until it can partner or sell the program. Meanwhile, Enzon Pharmaceuticals, in Bridgewater, N.J., cites poor market conditions as the reason it has decided not to spin off its biotech business as a separate company.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X